CASE REPORT

A puerperal patient with agranulocytosis during tazobactam/piperacillin administration: A case report

Haruna Iwazawa¹, Hiroaki Tanaka¹, Takakiyo Tatsumichi¹, Kazunori Yamaguchi¹, Koichi Takahashi¹, Kiyoh Suzuki¹, Takahiro Motoki¹, Kenji Kanenishi², and Shinji Kosaka¹

¹Department of Pharmacy, Kagawa University Hospital, Ikenobe, Miki, Kagawa, Japan; ²Department of Perinatology and Gynecology, Kagawa University Graduate School of Medicine, Ikenobe, Miki, Kagawa, Japan

Abstract: Tazobactam/piperacillin (TAZ/PIPC) is an injectable combination drug consisting of a broad-spectrum penicillin and a β-lactamase inhibitor. This antimicrobial has a wide spectrum of efficacy against both Gram-positive bacteria and anaerobes. Adverse events usually present as diarrhea or liver dysfunction; agranulocytosis has not been reported in Japanese patients with puerperal disorders. However, we report a 32-year-old Japanese woman who received TAZ/PIPC to treat an intraperitoneal infection that developed after complications related to transvaginal delivery. Within 14 days of beginning TAZ/PIPC therapy, the patient developed agranulocytosis, indicated by a white blood cell count of 1900 cells/µL and a neutrophil count of 475 cells/µL. We discontinued TAZ/PIPC at this point and changed the antimicrobial to meropenem. Seven days later, her white blood cell count increased to 3700 cells/µL (neutrophil count: 1684 cells/µL), and the intraperitoneal infection resolved. Patients receiving TAZ/PIPC should be monitored periodically for agranulocytosis as well as for diarrhea and liver dysfunction. J. Med. Invest. 68: 368-371, August 2021

Keywords: piperacillin-tazobactam, agranulocytosis, neutropenia, puerperium

INTRODUCTION

Tazobactam/piperacillin (TAZ/PIPC) is a combination antibiotic preparation for injection consisting of a β-lactamase inhibitor, tazobactam (TAZ), and a penicillin antibiotic, piperacillin (PIPC), at a ratio of 1:8 (1). As TAZ/PIPC has a broad antimicrobial spectrum against Gram-positive bacteria, such as Staphylococcus, gram-negative bacteria, including Pseudomonas aeruginosa, and anaerobic bacteria (2), it is routinely used clinically to treat many infectious diseases (3). In Japan, the drug’s indications for pneumonia, pyelonephritis, and peritonitis are covered by health insurance. In the Guidelines for the Treatment of Respiratory Infectious Diseases, TAZ/PIPC is recommended as a first-choice drug for hospital-acquired pneumonia (HAP), nursing- and healthcare-associated pneumonia (NHCAP), and severe pneumonia (4). In the United States, TAZ/PIPC and carbapenem preparations are recommended as drugs for monotherapy in the guidelines for the management of intraperitoneal infectious diseases collaboratively announced by the Surgical Infection Society and Infectious Diseases Society of America in 2010. As primary adverse reactions, diarrhea and liver dysfunction have been reported, but no case report of agranulocytosis as a serious adverse event has been published in Japanese patients with puerperal disorders. We report a patient in whom the administration of TAZ/PIPC for intraperitoneal infection during puerperium may have induced agranulocytosis.

CASE PRESENTATION

Patient: A 32-year-old female patient.

Complaint: Delivery.

Medical history: Hypothyroidism.

Therapeutic drug: Levethoxine sodium hydrate.

Obstetric history: Nulliparous.

Allergy: Not contributory.

Present illness: She was admitted due to premature rupture of the fetal membranes (Day 5 in Week 39 of pregnancy).

Laboratory data on admission: The laboratory data on admission are presented in the Table. Physical examination on admission: The patient’s height, body weight, body temperature, heart rate, and blood pressure

Table. Laboratory data on Day 4

| WBC    | 98.40 ×10⁹/µL | TP   | 6.4 g/dL |
|--------|---------------|------|---------|
| Seg    | 83.2 %        | ALB  | 3.0 g/dL |
| Eosin  | 0.0 %         | AST  | 16 U/L  |
| Lymph  | 0.2%          | ALT  | 8 U/L   |
| Mono   | 11.7%         | LDH  | 184 U/L |
| Mono   | 4.9%          | BUN  | 5.6 mg/dL |
| RBC    | 40.4 ×10⁹/µL  | Cr   | 0.37 mg/dL |
| HGB    | 10.8 g/dL     | eGFR | 157.3 mL/min |
| PLT    | 20.3 ×10⁹/µL  | CRP  | 5.68 mg/dL |

Table: white blood cell count, Seg: segmented neutrophils, Eosin: eosinophils, Lymph: lymphocytes, Mono: monocytes, RBC: red blood cells, HGB: hemoglobin, PLT: platelets, TP: total protein, ALB: albumin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, BUN: blood urea nitrogen, Cr: creatinine, eGFR: estimated glomerular filtration rate, CRP: C-reactive protein

Received for publication September 25, 2020; accepted March 14, 2021.

Address correspondence and reprint requests to Hiroaki Tanaka, Department of Pharmacy Kagawa University Hospital, 1750-1 Ikenobe, Miki, Kagawa 761-0793, Japan and Fax: +81-87-891-2318.
were 155.8 cm, 54.5 kg, 37.2°C, 115 beats/min, and 130/87 mmHg, respectively.

Course after admission: After admission, delivery was induced using oxytocin, and on Day 4, a neonate was born by transvaginal delivery. After delivery, placental separation-related hemorrhage persisted, making management by ligation and blood transfusion difficult; therefore, total hysterectomy was performed on the same day. From Day 8, fever (≥38°C) persisted, and blood culture revealed \textit{Bacteroides fragilis} on Day 9, suggesting intraperitoneal infection as an etiological factor. TAZ/PIPC therapy (4.5 g, every 8 hours) was started. Subsequently, the leukocyte count gradually decreased to 1900/µL on Day 23 (neutrophil count: 475/µL), leading to a diagnosis of agranulocytosis. There was no change in the red blood cell count (RBC). There was a slight decrease in the platelet count (PLT), but the value did not meet the diagnostic criterion for thrombocytopenia. In addition, there were no changes in the eosinophil or basophil count in comparison with the values at admission.

Drug-induced agranulocytosis was suspected, and TAZ/PIPC administration was promptly discontinued. Considering the drug susceptibility of \textit{Bacteroides fragilis} and breast milk transfusion, TAZ/PIPC was changed to meropenem (MEPM) (1 g every 8 hours). Subsequently, granulocyte-colony stimulating factor (G-CSF) was not used, and the leukocyte count returned to 3920/µL on Day 27 (neutrophil count: 1784/µL). Concerning the intraperitoneal infection, a reduction in the inflammatory response and fever resolution were noted 2 weeks after confirming a negative blood culture. MEPM therapy ended on Day 30. Subsequently, there was no recurrence of agranulocytosis or intraperitoneal infection, and the patient was discharged on Day 38 (Fig.).

DISCUSSION

We report a patient with agranulocytosis related to TAZ/PIPC administration during puerperium. Agranulocytosis related to drugs, excluding anticancer drugs, is characterized by a neutrophil count of ≤500/µL, and this adverse event is rare (5). Its incidence is 1–5 person-years per 1,000,000 persons (6). Drugs are involved in the etiology of agranulocytosis in approximately 70% of patients (7).

As drugs that frequently cause agranulocytosis, anti-thyroid drugs, antibiotics, and antipsychotics are known, but only a few patients with TAZ/PIPC-induced agranulocytosis have been reported (8-12); no puerperal patient has been reported. A definitive diagnosis of drug-induced agranulocytosis can be made if there is a decrease in the granulocyte count after drug administration in the absence of other factors causing granulocytopenia. However, a decrease in the granulocyte count is not rare in severe-status patients, especially those with infection. Conditions to be differentiated from acute agranulocytosis are viral/bacterial infection, bone marrow failure syndrome, hypersplenism, and drug-induced agranulocytosis (13). In the present case, we were unable to definitively conclude that TAZ/PIPC induced the granulocytopenia. However, considering the reduction in the abscess after the start of TAZ/PIPC therapy and the patient’s recovery from protracted leukopenia to a leukocyte count of 5480/µL (neutrophil count: 3162/µL) 12 days after discontinuing TAZ/PIPC administration despite few imaging findings suggestive of infection, TAZ/PIPC may have been etiologically involved in the protracted granulocytopenia in the present case. In addition to TAZ/PIPC, levothyroxine sodium was administered before admission to treat hypothyroidism; however, no study has reported agranulocytosis related to levothyroxine sodium. Moreover, hematology on admission revealed no abnormalities in the leukocyte or neutrophil counts. Therefore, the possibility of levothyroxine sodium-induced agranulocytosis was excluded, and TAZ/PIPC may have induced the agranulocytosis. However, bone marrow examination was not conducted and a definitive diagnosis was not made, being a limitation.

Although the etiology of drug-induced agranulocytosis remains unclear; two mechanisms, direct toxicity and an immune mechanism, have been proposed (14).
In Japan, the reported incidences of TAZ/PIPC- and PIPC-induced agranulocytosis are 0.1 to 5% and unclear, respectively, in the package inserts. We searched for “agranulocytosis” using a system to search for adverse reactions to drugs based on the “Japanese Adverse Drug Event Report database” announced on the Pharmaceuticals and Medical Devices Agency (PMDA) homepage, Drug Information Finding Outcomes (DRIFOs). For the respective drugs, 30 and 14 patients were found, respectively. There was no puerperal disorder in either series. TAZ/PIPC used in the present case is a combination drug that may induce adverse reactions. However, there is no commercially available product consisting of TAZ alone and no study has reported that the addition of TAZ to PIPC increases the risk of adverse reactions; therefore, comparison may be difficult. On the other hand, penicillin-induced agranulocytosis has been reported; therefore, in the present case, the adverse reaction may have been related to PIPC.

Regarding the cross-reactivity of TAZ/PIPC and MEMP, the probability of cross-reactions with carbapenems in patients with penicillin allergy was previously considered to be approximately 50%. However, this was based on a single study involving a small number of patients (15). A recent study reported that cross-reactions with carbapenems occurred in <1% of patients with penicillin allergy (16).

Concerning direct toxicity, antiepileptic and psychotropic drugs were reported to directly act on myeloid cells. The toxicity is induced by the drug itself, a toxic metabolite, or an accessory product. Leukopenia related to direct toxicity develops slowly. In comparison, an immune mechanism is termed a “drug allergy” in some cases, and drug adsorption/immune complex/autoimmune mechanisms are known to occur. The onset of a drug allergy is more rapid than a toxicity. Antibody is produced within 1 hour to 1 day in patients previously sensitized to the drug, and in 7–10 days in non-sensitized patients. Concerning penicillin antibiotics, an immune mechanism may be involved in the onset of agranulocytosis. In the present case, leukocytopenia and neutropenia were observed 14 days after the administration of TAZ/PIPC. This is consistent with the timing of agranulocytosis onset possibly related to an immune mechanism, which is supported by previous studies stating that adverse reactions developed 11–17 days after the use of TAZ/PIPC (11, 17). Furthermore, the risk factors for agranulocytosis are advanced age, female sex, renal hypofunction, and autoimmune diseases (18, 19). However, in the present case, the patient was 32 years old, and the creatinine clearance (Ccr) (Cockcroft–Gault equation) was 165.58 mg/dL; there was no renal hypofunction. There was also no history of autoimmune disease.

The agranulocytosis-related mortality rate with TAZ/PIPC is approximately 10%, and agranulocytosis accounts for 20%–30% of drug-related deaths, and is the most frequent causative factor. As protracted/severe neutropenia increases the mortality rate, initial management is important. Therefore, when administering TAZ/PIPC to puerperal patients, neutrophil counts should be monitored to detect agranulocytosis, in addition to monitoring for diarrhea and evaluating liver function.

In the present case, bacteremia due to hospital-onset intrapartum infection was noted. To cover the Gram-positive bacteria suspected to be the causative bacteria in addition to *Bacteroides fragilis*, which was detected on blood culture, CFPM + CLDM or MNZ, a quinolone + CLDM or MNZ, or carbapenem antibiotics are considered options. In the present case, it was necessary to select a highly safe drug with low breast milk transfer, considering lactation. CLDM may affect the intestinal flora of children fed breast milk. The carcinogenicity of MNZ in animals and its mutagenicity in humans were previously demonstrated; therefore, healthy infants may be exposed to metronidazole via breast milk (20). Considering the safety, according to these studies, MEMP with its low-level breast milk transfer was proposed as an alternative to TAZ/PIPC (21), preventing the unnecessary discontinuation of lactation.

In conclusion, we reported a patient with agranulocytosis related to TAZ/PIPC administered during the puerperal period. On the basis on the patient’s previous drug administration history, we considered that agranulocytosis was related to TAZ/PIPC and discontinued the drug, resulting in recovery. When administering TAZ/PIPC, neutrophil counts should be monitored to detect agranulocytosis, in addition to monitoring for diarrhoea and evaluating liver function. Furthermore, drug administration should be discontinued at the onset of agranulocytosis, and TAZ/PIPC should be changed to other drugs, if necessary.

**ETHICS APPROVAL**

This study was performed according to the guidelines of the Declaration of Helsinki, and approved by the ethics committee of Kagawa University (Approval No. 2019-157). Written informed consent was received from the patient for publication of this case report.

**CONFLICT OF INTEREST**

None of the authors have any potential conflicts of interest associated with this research.

**REFERENCES**

1. ZOSYN® Interview form, 18th ed. Taisho Toyama Pharmaceutical & Co., Ltd., Tokyo, 2020
2. Perry CM, Markham A : Piperacillin/tazobactam : an updated review of its use in the treatment of bacterial infections. Drugs 57 : 805-843, 1999
3. Nishida K, Higashitani F, Hyodo A : Superior effect of tazobactam/piperacillin compared to piperacillin on beta-lactamase-producing Pseudomonas aeruginosa. Chemotherapy 43 : 171-178, 1997
4. The Japanese Association for Infectious Diseases (JAIID), Japanese Society of Chemotherapy (JSC) : Guidelines for Treatment of Respiratory Infectious Diseases, JAIID, JSC. Tokyo : 21-48, 2014
5. Andersohn F, Konzen C, Garbe E : Systematic review : agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146 : 657-665, 2007
6. Kaufman DW, Kelly JP, Junker-KM, Anderson T, Issaragrisil S, Wiholm BE, Young NS, Leaverton P, Levy M, Shapiro S : Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 60 : 23-30, 1996
7. Kaufman DW, Kelly JP, Issaragrisil S, Laporte-JR, Anderson T, Levy M, Shapiro S, Young NS : Relative incidence of agranulocytosis and aplastic anaemia. Am J Hematol 8 : 65-67, 2006
8. Lee KW, Chow KM, Chan NP, Lo AO, Szeto CC : Piperacillin/tazobactam Induced myelosuppression. J Clin Med Res 1 : 53-55, 2009
9. Macwilliam JL, Mistry R, Floyd MS Jr, Baird AD : Piperacillin/tazobactam induced thrombocytopenia--a delayed response. BMJ Case Rep 2012
10. Nguyen V, Tournigry JF, Roy R, Brauilliette D : Rapid-onset thrombocytopenia following piperacillin-tazobactam reexposure. Pharmacotherapy 35 : e326-e330, 2015
11. Ruiz-Irastorza G, Barreiro G, Aguirre C: Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol 95: 611-612, 1996
12. Chen H, Fan Z, Guo F, Yang Y, Li J, Zhang J, Wang Y, LE J, Wang Z, Zhu J: Tazobactam and piperacillin-induced thrombocytopenia: a case report. Exp Ther Med 11: 1223-1226, 2016
13. Boxer LA: Neutropenia. In: Sills RH, eds. Practical Algorithms in Pediatric Hematology and Hematology and Oncology. S. Karger AG, Albany, 2003, 42-43
14. Pisciotta AV: Immune and toxic mechanisms in drug-induced agranulocytosis. Semin Hematol 10: 279-310, 1973
15. Saxon A, Adelman DC, Patel A, Hajdu R, Calandra GB: Imipenem cross-reactivity with penicillin in humans. J Allergy Clin Immunol 82(2): 213-7, 1988
16. Atanaskovic-Markovic M, Gaeta F, Medjo B, Viola M, Nestorovic B, Romano A: Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. Allergy 63(2): 237-40, 2008
17. Reichardt P, Handrick W, Linke A, Schille R, Kiess W: Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment—a retrospective analysis in 38 children with cystic fibrosis. Infection 27: 355-356, 1999
18. Kaufman DW, Kelly JP, Levy M, Shapiro S: Drug etiology of agranulocytosis: an update of the international agranulocytosis and aplastic anemia study. Pharmacoepidemiol Drug Saf 2: S25-S29, 1993
19. Young NS: Agranulocytosis. JAMA 271: 935-938, 1994
20. American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk. Pediatrics 108: 776-789, 2001
21. Sauberan JB, Bradley JS, Blumer J, Stellwagen LM: Transmission of meropenem in breast milk. Pediatr Infect Dis J 31: 832-834, 2012